ReproCELL
Integrated research and medical company specializing in iPS and ES cell technologies for drug discovery and regenerative medicine.
- CEO / Founder
- Chikafumi Yokoyama (Global CEO), Rama Modali (CEO, REPROCELL USA)
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $21.7M+
- Latest Round
- Grant
- Key Investors
- NorthStar Ventures, Business Investment Group (BiG), Mitsubishi UFJ Capital, SBI Investment, Nissay Capital, DBJ Capital, Maryland Stem Cell Research Fund
Technology & Products
Key Products
iPSC-derived cell products, GMP manufacturing services, human tissue research services, stem cell technologies for drug discovery and regenerative medicine.
Technological Advantage
Integrated platform spanning research reagents, drug discovery assays, and MHLW-licensed clinical-grade cell processing (CDMO).
Differentiation
Value Proposition
Accelerates drug discovery and regenerative medicine through high-quality iPSC-derived cell products and integrated GMP manufacturing services, reducing clinical development risks.
How They Differentiate
First-mover advantage in iPSC commercialization and a global footprint established through strategic acquisitions of BioServe, Stemgent, Reinnervate, and Biopta.
Market & Competition
Target Customers
Pharmaceutical companies, academic researchers, medical device manufacturers, and regenerative medicine providers.
Industry Verticals
Pharmaceutical; Medical; Academic Research; Biotechnology
Competitors
Cyfuse Biomedical, Organovo, Cellink
Growth & Milestones
Growth Metrics
Publicly listed on Tokyo Stock Exchange (4978); Capital of ¥2,688M; Global operations in Japan, USA, UK, and India.
Major Milestones
2003: Founded by Profs. Nakatsuji and Nakauchi; 2005: Launched first human ES cell culture medium; 2009: Launched world's first iPSC-derived cardiomyocytes; 2013: Listed on Japan JASDAQ / Growth stock market; 2014: Acquired Reinnervate (Alvetex 3D cell culture); 2022: Completed Phase II clinical trial of Stemchymal
Notable Customers
Ajinomoto, Steminent Biotherapeutics